1. The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis
- Author
-
Chia Ning Chang, Chia Hao Chan, Tz Heng Chen, Szu Yuan Li, Chih Yuan Niu, Wen Sheng Liu, Chih Ching Lin, Chun Fan Chen, Ann Charis Tan, Yung Tai Chen, Fan Yu Chen, and Guor Jien Wei
- Subjects
Male ,medicine.medical_treatment ,030232 urology & nephrology ,Gastroenterology ,lcsh:Chemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Dialysis Solutions ,Peritoneal transport rate ,lcsh:QH301-705.5 ,Spectroscopy ,Dialysis adequacy ,Glucose degradation ,Methylglyoxal ,General Medicine ,Middle Aged ,Computer Science Applications ,glucose degradation products ,peritoneal dialysis ,diabetes mellitus ,Female ,Adult ,medicine.medical_specialty ,Encapsulating Peritoneal Sclerosis ,Infrared Rays ,Article ,Catalysis ,Peritoneal dialysis ,Diabetes Complications ,Inorganic Chemistry ,03 medical and health sciences ,far-infrared therapy ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Aged ,business.industry ,Organic Chemistry ,medicine.disease ,Glucose ,lcsh:Biology (General) ,lcsh:QD1-999 ,chemistry ,Kidney Failure, Chronic ,Complication ,business ,030217 neurology & neurosurgery - Abstract
Peritoneal dialysis (PD) is a treatment modality for end-stage renal disease (ESRD) patients. Dextrose is a common osmotic agent used in PD solutions and its absorption may exacerbate diabetes mellitus, a common complication of ESRD. PD solutions also contain glucose degradation products (GDPs) that may lead to encapsulating peritoneal sclerosis (EPS), a severe complication of PD. A previous study showed that far-infrared (FIR) therapy improved a patient’s gastrointestinal symptoms due to EPS. Due to limited literature on the matter, this study aims to investigate dialysate GDPs and peritoneal function in diabetic patients on PD. Thirty-one PD patients were enrolled and underwent 40 min of FIR therapy twice daily for six months. We demonstrated the effect of FIR therapy on the following: (1) decrease of methylglyoxal (p = 0.02), furfural (p = 0.005), and 5-hydroxymethylfurfural (p = 0.03), (2) increase of D/D0 glucose ratio (p = 0.03), and (3) decrease of potassium levels (p = 0.008) in both DM and non-DM patients, as well as (4) maintenance and increase of peritoneal Kt/V in DM and non-DM patients, respectively (p = 0.03). FIR therapy is a non-invasive intervention that can decrease dialysate GDPs in PD patients by improving peritoneal transport rate and solute removal clearance, while also maintaining dialysis adequacy.
- Published
- 2021
- Full Text
- View/download PDF